Last updated on August 2019

Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial


Brief description of study

A multicenter, non-randomized, open label trial, to assess long term safety and efficacy of Arimoclomol in subjects with Amyotrophic Lateral Sclerosis (ALS)who have completed the ORARIALS-01 trial.

Clinical Study Identifier: NCT03836716

Find a site near you

Start Over

HonorHealth Neurology

Phoenix, AZ United States
  Connect »

University of Miami

Miami, FL United States
  Connect »

Hospital for Special Surgery

New York, NY United States
  Connect »

University of Virginia Health System

Charlottesville, VA United States
  Connect »